



## Cue Biopharma to Provide Corporate Update at the 10th Annual Biotech Showcase 2018 Conference

January 4, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- [Cue Biopharma](#)™, Inc., (NASDAQ:CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it will be featured as a presenting company at the upcoming 10th Annual Biotech Showcase Conference™ on January 9, 2018, in San Francisco, CA.

### Presentation details:

- Date: Tuesday, January 9, 2018
- Time: 11:15 am PT
- Duration: 15 minutes
- Location: Franciscan Room B at the Ballroom Level of the Hilton San Francisco Union Square

Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma, will provide an overview of the Company's technology platform and overall development strategy and give updates on key programs, including anticipated development milestones.

### **About Cue Biopharma**

Cue Biopharma™ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient's body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects.

We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform™. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost-efficiently than current industry standard timelines and costs.

Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit [www.cuebio.com](http://www.cuebio.com).

### **Forward-Looking Statements**

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recently filed Registration Statement on Form S-1, which can be found on the SEC's website at [www.sec.gov](http://www.sec.gov). We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20180104006248/en/>

Source: Cue Biopharma

### **Investors:**

Cue Biopharma  
Kerri-Ann Millar, 617-949-2602

or

### **Media:**

Sam Brown Inc.

Cory Tromblee, 617-571-7220